Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 2, 2002 - Issue 3
Submit an article Journal homepage
41
Views
11
CrossRef citations to date
0
Altmetric
Review

Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis

Ivar Sønbø Kristiansen Institute of Public Health - Health Economics Research Unit, University of Southern Denmark, Odense, 19 Winsløw Park, DK-5000 Odense C, Denmark. [email protected]
&
Tore Kristian Kvien Diakonhjemmet Hospital, Oslo City Department of Rheumatology, PO Box 23 Vindern, N-0319 Oslo, Norway. [email protected]
Pages 229-241 | Published online: 09 Jan 2014

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Louis Bessette, Nancy Risebrough, Nicole Mittmann, Jean-Pascal Roussy, Joanne Ho & Gergana Zlateva. (2009) Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. Journal of Medical Economics 12:3, pages 246-258.
Read now
Monica Schaefer, Melissa DeLattre, Xin Gao, Jennifer Stephens, Marc Botteman & Anthony Morreale. (2005) Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Current Medical Research and Opinion 21:1, pages 47-60.
Read now

Articles from other publishers (9)

Luis Hermenegildo Martín Arias, Antonio Martín González, Rosario Sanz Fadrique & Esther Salgueiro Vázquez. (2019) Gastrointestinal safety of coxibs: systematic review and meta-analysis of observational studies on selective inhibitors of cyclo-oxygenase 2. Fundamental & Clinical Pharmacology 33:2, pages 134-147.
Crossref
Soo-Jin ChungHye-Jin ParkMin-Chan Park. (2017) Cost-effectiveness of Non-steroidal Anti-inflammatory Drugs Adjusting for Upper and Lower Gastrointestinal Toxicities in Rheumatoid Arthritis Patients. Journal of Rheumatic Diseases 24:1, pages 27.
Crossref
Ronald C. Wielage, Julie A. Myers, Robert W. Klein & Michael Happich. (2013) Cost-Effectiveness Analyses of Osteoarthritis Oral Therapies: a Systematic Review. Applied Health Economics and Health Policy 11:6, pages 593-618.
Crossref
Saharat Jarupongprapa, Prapassorn Ussavasodhi & Wanruchada Katchamart. (2012) Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. Journal of Gastroenterology 48:7, pages 830-838.
Crossref
Ronald C. Wielage, Megha Bansal, J. Scott Andrews, Robert W. Klein & Michael Happich. (2013) Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective. Applied Health Economics and Health Policy 11:3, pages 219-236.
Crossref
Tjeerd-Pieter van Staa, Hubert G. Leufkens, Bill Zhang & Liam Smeeth. (2009) A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example. PLoS Medicine 6:12, pages e1000194.
Crossref
Iris Contreras-Hernández, Joaquín F Mould-Quevedo, Rubén Torres-González, María Victoria Goycochea-Robles, Reyna Lizette Pacheco-Domínguez, Sergio Sánchez-García, Juan Manuel Mejía-Aranguré & Juan Garduño-Espinosa. (2008) Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. Cost Effectiveness and Resource Allocation 6:1.
Crossref
Yuhong Yuan & Richard H. Hunt. (2003) Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?. InflammoPharmacology 11:4-6, pages 337-354.
Crossref
Mary L. Chavez & Carrie J. DeKorte. (2003) Valdecoxib: A review. Clinical Therapeutics 25:3, pages 817-851.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.